ACRX:NSD-AcelRx Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 0.61

Change

-0.01 (-1.46)%

Market Cap

USD 0.07B

Volume

0.73M

Avg Analyst Target

USD 5.00 (+716.19%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AcelRx Pharmaceuticals Inc (ACRX) Stock Analysis:
Based on the AcelRx Pharmaceuticals Inc stock forecasts from 1 analysts, the average analyst target price for AcelRx Pharmaceuticals Inc is USD 5.00 over the next 12 months. AcelRx Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AcelRx Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, AcelRx Pharmaceuticals Inc’s stock price was USD 0.61. AcelRx Pharmaceuticals Inc’s stock price has changed by -0.06 % over the past week, -0.29 % over the past month and -57.16 % over the last year.

About

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to- ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-02 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

-0.15 (-0.19%)

USD8.04B 17.79 39.74
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
TLRY Tilray Inc

+0.27 (+2.91%)

USD4.69B N/A N/A
CGC Canopy Growth Corporation

+0.42 (+4.23%)

USD4.22B N/A N/A
ITCI Intra-Cellular Therapies Inc

+0.08 (+0.21%)

USD3.33B N/A N/A
PCRX Pacira BioSciences Inc

+0.46 (+0.86%)

USD2.28B 39.33 17.58
DVAX Dynavax Technologies Corporati..

-0.41 (-2.71%)

USD1.93B N/A 98.57
IRWD Ironwood Pharmaceuticals Inc

+0.17 (+1.55%)

USD1.78B 3.37 7.24

ETFs Containing ACRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -50.60% 28% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.60% 28% F 13% F
Trailing 12 Months  
Capital Gain -57.16% 21% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.16% 21% F 8% F
Trailing 5 Years  
Capital Gain -77.72% 24% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.72% 24% F 7% F
Average Annual (5 Year Horizon)  
Capital Gain -8.28% 31% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.28% 31% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 41.97% 60% D- 43% F
Risk Adjusted Return -19.73% 34% F 12% F
Market Capitalization 0.07B 22% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -1.93 38% F 58% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 163.39% 100% A+ 99% A+
Return on Assets -33.44% 18% F 10% F
Debt to Equity Ratio -23.57% 82% B- 94% A
Technical Ratios  
Short Ratio 3.54 51% F 40% F
Short Percent 2.67% 74% C 50% F
Beta 0.71 76% C 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector